# Safety and Efficacy of EVT 101 in Treatment-Resistant Depression

> **NCT01128452** · PHASE2 · TERMINATED · sponsor: **Janssen Research & Development, LLC** · enrollment: 8 (actual)

## Conditions studied

- Depression

## Interventions

- **DRUG:** EVT 101
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01128452
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-06
- **Primary completion:** 2011-03
- **Final completion:** 2011-03
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** Evotec has indicated that this study was discontinued due to a clinical hold issued by the FDA
- **Last updated:** 2016-03-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01128452

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01128452, "Safety and Efficacy of EVT 101 in Treatment-Resistant Depression". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01128452. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*